Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Johnson & Johnson : J&J in $4 Billion Settlement Talks

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/12/2013 | 11:16pm CET

Johnson & Johnson (JNJ) has agreed to pay $4 billion to settle more than 7,500 lawsuits over the company's recalled hip-implant products, Bloomberg News reported Tuesday, citing three people familiar with the agreement.

The settlement will be announced next week, Bloomberg reported.

Full story at: www.bloomberg.com/news/2013-11-12/j-j-said-to-reach-4-billion-deal-to-settle-hip- awsuits.html

Write to nymonitoring@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
02/24 JOHNSON & JOHNSON : Remarks by President Trump at Signing of Executive Order on ..
02/24 JOHNSON & JOHNSON : Fourth Talcum Powder Lawsuit Heads to Trial in Missouri Ovar..
02/24 JOHNSON & JOHNSON : ex-dividend day
02/23 JOHNSON & JOHNSON : S&P upgrades Google's owner to its second-highest ranking
02/23 JOHNSON & JOHNSON : Anti-diarrhea medication ripe for abuse by opioid addicts, a..
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21 JOHNSON & JOHNSON : Ford Still Can Repair its Brand in South Africa but it Needs..
02/21 JOHNSON & JOHNSON : Ford still can repair its brand in South Africa but it needs..
02/20 MEDTRONIC : Global High Speed Surgical Drill Market- Medtronic, Johnson and John..
More news
Sector news : Pharmaceuticals - NEC
02/24DJSHIRE : Files 8K - Other Events
02/24DJASTRAZENECA : Hyperkalaemia Drug Clears Scientific Hurdle for European Approval
02/24DJASTRAZENECA : Gets Approval for Drug Treating Hyperkalaemia
02/24 Exclusive - Trump says Republican border tax could boost U.S. jobs
02/23DJPFIZER : Files 8K - Changes Executive Management
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/24 UPCOMING EVENTS : J&J And NeuroDerm Put New Delivery Routes To The Test
02/24 A Dividend Portfolio Built From The World's Best Dividend ETFs
02/24 ValueAct Capital Is Going Risk-Off. Right Or Wrong?
02/24 SYNERGY : 3 Scenarios, 1 Choice
02/24 Europe's CHMP backs expanded use of Janssen Biotech's Darzalex
Advertisement
Financials ($)
Sales 2017 74 655 M
EBIT 2017 23 131 M
Net income 2017 18 272 M
Finance 2017 22 793 M
Yield 2017 2,75%
P/E ratio 2017 18,25
P/E ratio 2018 17,10
EV / Sales 2017 4,13x
EV / Sales 2018 3,90x
Capitalization 331 089 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 125 $
Spread / Average Target 3,0%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.74%331 089
ROCHE HOLDING LTD.5.98%209 906
PFIZER INC.3.42%206 688
NOVARTIS AG3.51%201 806
MERCK & CO., INC.10.91%181 558
SANOFI4.38%109 628
More Results